360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Xarelto

Type: Product

Name: Xarelto

First reported 23 hours ago - Updated 23 hours ago - 1 reports

infliximab

Can Johnson & Johnson fire on all cylinders again?

Shares of Johnson & Johnson are up 40% over the past year, but the rally hasn't accompanied strong, even financial performance, especially from its struggling medical device segment.In what has become a red-hot stock market for medtech stocks, it's the ... [Published MassDevice - 23 hours ago]

Entities: Johnson & Johnson, Drugs, infliximab, Xarelto

First reported May 12 2013 - Updated May 13 2013 - 1 reports

Our Limitless Capacity For Self-Deception

I want to share with my readers . The original post is by Eric Lindley, a cardiology fellow at the University of Utah:Journal X: Not so Subtle Marketing MessagesI was the rare resident who thought that conflict of interest issues in medicine were a bit ... [Published Forbes.com - May 12 2013]

Entities: Stent, Cardiology, Rivaroxaban, Xarelto

First reported May 11 2013 - Updated May 11 2013 - 1 reports

FDA Food & Drug Administration

FDA approves a drug to reverse anticoagulation

Ever since the drug warfarin was discovered to be a highly effective anti-clotting agent as well as a good rat poison in the early 1950s, it has been the frontline weapon in preventing stroke among those with atrial fibrillation. But its growing use has ... [Published Greater Milwaukee Today - May 11 2013]

Entities: Warfarin, FDA Food & Drug Administration, Atrial Fibrillation, Coagulation, Drugs

First reported May 09 2013 - Updated May 09 2013 - 1 reports

Johnson & Johnson

Johnson & Johnson Stock Is on the Mend

Filed under: InvestingJohnson & Johnson stock is turning around in a big way.After seeing revenue decline two years in a row , the company posted two years of revenue growth, and first-quarter revenue was up a solid 8.5%.Investors are convinced this isn't ... [Published Daily Finance - May 09 2013]

Entities: Johnson & Johnson, Motley Fool, Vertex Pharmaceuticals Inc

First reported May 09 2013 - Updated May 09 2013 - 1 reports

An Anticoagulant Antidote

Here's a drug-discovery problem that you don't often have to think about. The anticoagulant field is a huge one, with Plavix, warfarin, and plenty of others jostling for a share of a huge market (both for patients to take themselves, and for hospital ... [Published In the Pipeline - May 09 2013]

Entities: Anticoagulant, Antidote, Warfarin, Rivaroxaban, Xarelto

First reported May 07 2013 - Updated May 07 2013 - 1 reports

Pfizer Inc

An Update On Pfizer's Recently Approved Drugs

Pfizer's stock (PFE) has been on a nice run the last year despite facing a host of patent expirations. While stock repurchases and spin-offs have helped, I believe most of this growth in the stock price is because Pfizer's pipeline is finally producing ... [Published Seeking Alpha - May 07 2013]

Entities: Pfizer Inc, Drugs, ELIQUIS

First reported May 05 2013 - Updated May 05 2013 - 1 reports

Kuwait campaign to raise awareness about stroke

Dr. Riccardo Cappato, Dr. Mousa Akbar, Dr. Anthonie W.A.Lesing and Dr. Faisal Al-SayeghKUWAIT: Bayer Healthcare launched a campaign in Kuwait to raise awareness about stroke and the latest remedies developed to prevent and cure this lethal disease that ... [Published Kuwait Times - May 05 2013]

Entities: Anticoagulant, Coagulation, Warfarin, Patient, Kuwait

First reported Apr 30 2013 - Updated Apr 30 2013 - 1 reports

Medicines board says it has ‘no immediate issues’ with blood thinners despite reactions

The Irish Medicines Board says it has "no immediate issues" with a number of leading new blood thinners which have been the subject of hundreds of adverse reactions since they were introduced.The board has received 109 reports of suspected adverse reactions ... [Published Irish Times - Apr 30 2013]

Entities: Pradaxa, Warfarin, Patient, Michael Barry, Rivaroxaban

First reported Apr 25 2013 - Updated Apr 25 2013 - 4 reports

Bayer drug sales up 2.3%, as new products offset older drugs' suffering

Poor Bayer HealthCare. Its new drugs and modest sales growth couldn't make up for lagging sales and soaring costs at Bayer's plastics business. Announcing its first-quarter results, Bayer Group understandably leaned on its healthcare unit's strengths, ... [Published FiercePharma - Apr 25 2013]

Entities: Bayer AG, Drugs, Eylea, Stivarga

First reported Apr 25 2013 - Updated Apr 25 2013 - 1 reports

Bayer cuts plastics outlook, as higher costs hurt

Factors to watch on April 24 First-quarter adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) edged 0.4 percent higher to 2.45 billion euros ($3.18 billion), which was slightly below the average estimate in a Reuters poll ... [Published Reuters - Apr 25 2013]

Entities: Bayer AG, Plastics, EBITDA

First reported Apr 25 2013 - Updated Apr 25 2013 - 1 reports

Look Who Filmed a Music Video in South Pas

The biggest name to shoot in South Pasadena recently is the original American Idol herself, Kelly Clarkson.Clarkson's production company shot a music video on April 9 in the 800 block of Mission Street. The Grammy-award winning artist is teaming up with ... [Published South Pasadena Patch - Apr 25 2013]

Entities: Xarelto, Kelly Clarkson, Kohl's

First reported Apr 22 2013 - Updated Apr 23 2013 - 2 reports

NICE recommends extending blood clot indication of Bayer’s Xarelto

Backs drug’s use to treat pulmonary embolism and prevent DVTBayer's oral anticoagulant Xarelto could soon be available to more patients in England and Wales after the National Institute for Health and Care Excellence (NICE) released draft guidance recommending ... [Published PMLive - Apr 23 2013]

Entities: Xarelto, Warfarin, Bayer AG

Quotes

...Ackman thinks this number is excessive. At Sohn, Ackman noted that "we make the conservative assumption that just attending board meetings and not including travel time, this accounts for 25% of his time."

Billionaire Bill Ackman: CEO's Clock Is Ticking [Published Motley Fool - May 16 2013]

...is the first time in a decade and its first global one ever that the company is indulging in a corporate re-brand ad campaign following recall of "millions of bottles and packages of Tylenol, Benadryl, Motrin and other over-the-counter medicines." One wonders whether the re-branding exercise was needed especially as it carries a risk of reminding customers of the mistakes committed earlier...

Johnson & Johnson: An Investment In A Healthcare Conglomerate That Cannot Go Wrong [Published Seeking Alpha - May 13 2013]

In a roomful of interventional cardiologists, the speaker asks, "How many of you have ever put in a stent that was unnecessary?" The speaker then asks, "How many of you have seen someone in this room put in a stent that was unnecessary?" About half the room raised their hands

Our Limitless Capacity For Self-Deception [Published Forbes.com - May 12 2013]

"We found that [continued warfarin therapy] is associated with a significantly lower rate of device-pocket hematoma, as compared with bridging therapy with heparin" the researchers concluded

Steady Warfarin Best for Cardiac Device Surgery [Published MedPage Today - May 11 2013]

More Content

sort by: Date \| Relevance
Can Johnson & Johnson fire on all cylinders again? [Published MassDevice - 23 hours ago]
Millions of Americans Die of Blood Clots [Published Bottom Line Publications - May 18 2013]
The Procter & Gamble Company (PG), Johnson & Jo... [Published InsiderMonkey.com - May 16 2013]
Billionaire Bill Ackman: CEO's Clock Is Ticking [Published Motley Fool - May 16 2013]
Buying Pfizer Stock Brings a Great Dividend [Published Motley Fool Discussion Boards - May 15 2013]
Diverging paths, difficult choices. Winter 2012 [Published Drug Discovery World - May 15 2013]
Johnson & Johnson: An Investment In A Healthcar... [Published Seeking Alpha - May 13 2013]
Our Limitless Capacity For Self-Deception [Published Forbes.com - May 12 2013]
FDA approves a drug to reverse anticoagulation [Published Greater Milwaukee Today - May 11 2013]
Steady Warfarin Best for Cardiac Device Surgery [Published MedPage Today - May 11 2013]
Boston Scientific’s Mahoney Says Watchman Devic... [Published BusinessWeek - May 10 2013]
Caution with switching warfarin to dabigatran [Published Medical Observer - May 10 2013]
HRS: Registry data point to shortfall in antico... [Published Cardiovascular Business - May 09 2013]
Johnson & Johnson Stock Is on the Mend [Published Daily Finance - May 09 2013]
An Anticoagulant Antidote [Published In the Pipeline - May 09 2013]
Portola Announces Its Factor Xa Inhibitor Antid... [Published Interest!ALERT - May 08 2013]
An Update On Pfizer's Recently Approved Drugs [Published Seeking Alpha - May 07 2013]
RU-486 subsidy won’t increase abortions: govt [Published Medical Observer - May 06 2013]
Kuwait campaign to raise awareness about stroke [Published Kuwait Times - May 05 2013]
Global oral anticoagulants market: Latest marke... [Published TransWorldNews - May 05 2013]
Clotting in lower legs potentially fatal [Published Florida Today - May 05 2013]
Johnson & Johnson's Stock Looks Too Healthy The... [Published Yahoo! Finance - May 01 2013]
Johnson & Johnson's Stock Looks Too Healthy [Published Daily Tribune - May 01 2013]
Johnson & Johnson's Stock Looks Too Healthy [Published TheStreet.com - May 01 2013]
Portola Pharmaceuticals, Inc. Announces Oral Pr... [Published BioSpace - Apr 30 2013]
Portola Pharmaceuticals, Inc. Announces Oral Pr... [Published BioSpace - Apr 30 2013]
Portola Announces Oral Presentation of Data on ... [Published Zecco - Apr 30 2013]
Medicines board says it has ‘no immediate issue... [Published Irish Times - Apr 30 2013]
PBAC recommendation no guarantee of PBS-listing... [Published Pharmacy News - Apr 29 2013]
Guide steers physicians through anticoagulant q... [Published Cardiovascular Business - Apr 29 2013]

Blogs

sort by: Date \| Relevance
An Anticoagulant Antidote [Published In the Pipeline - May 09 2013] Here's a drug-discovery problem that you don't often have to think about. The anticoagulant field is a huge one, with Plavix, warfarin, and plenty of others jostling for a share of a huge market (both for patients to take themselves, and for hospital ...
Bayer, Amgen Face Price Cuts as German Panel Ex... [Published PharmaGossip - Apr 19 2013] Bayer AG (BAYN) and Amgen Inc. (AMGN) are among drugmakers who may face price cuts as a German agency begins a broader review of the costs and benefits of medicines already on the market.Bayer’s blood thinner Xarelto, Amgen’s Prolia for osteoporosis and ...
Draft guidance from NICE recommends new treatme... [Published NICE \| National Institute for Health and Clinic ... - Apr 19 2013] NICE has issued final draft guidance recommending rivaroxaban (Xarelto, Bayer Healthcare) as a clinically and cost-effective option for treating pulmonary embolism (PE) and preventing recurrent deep vein thrombosis (DVT) and PE after acute PE in adul ...
Deals of the Week: An Update On A Potential Pfi... [Published The IN VIVO Blog - Mar 29 2013] br /> Pfizer's Chairman and CEO Ian Read doesn’t make himself available for interviews readily, so a March 26th note from Sanford Bernstein’s esteemed pharma analyst Tim Anderson caught our attention pronto. The note describes a teleconference call ...
Pending EC decision: Xarelto, rivaroxaban, Opin... [Published Pending EC decisions and European Public Assess ... - Mar 22 2013]

Press Releases

sort by: Date \| Relevance
Surveyed U.S. Physicians Indicate That Xarelto ... [Published PR Newswire: Entertainment & Media - Mar 27 2013]
Janssen Launches EXPLORER, Global Cardiovascula... [Published PR Newswire: Health - Mar 08 2013]
FDA Issues Complete Response Letter for XARELTO... [Published PR Newswire: Policy & Public Interest - Mar 04 2013]
XARELTO® to be Studied with Factor Xa Inhibitor... [Published PR Newswire: Health - Feb 05 2013]
Portola Enters Into Clinical Collaboration Agre... [Published Marketwire - Breaking News Releases - Feb 05 2013]